USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ADOLOR CORPORATION
Address:
371 PHOENIXVILLE PIKE
MALVERN, PA 19355
Phone:
(484) 595-1014
URL:
N/A
EIN:
311429198
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $363,119.00 4
SBIR Phase II $822,158.00 1

Award List:

IDENTIFICATION OF NOVEL LIGANDS FOR THE ORL-1 RECEPTOR

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$99,983.00
Agency:
HHS
Principal Investigator:
Dehaven-hudkins, diane l
Abstract:
N/a

Novel Cannabinoid Receptor Agonists as Analgesics

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$157,110.00
Agency:
HHS
Principal Investigator:
Robert N. Dehaven
Abstract:
DESCRIPTION (provided by applicant): Pain is a serious, debilitating condition that is undertreated because because of the dose-limiting side effects of currently used therapeutics. Agonists at the cannabinoid (CB) receptors, including delta-9-tetrahydrocannabinol, have… More

Discovery of K Opioid Analgesics Using Chimeric Receptor

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$106,026.00
Agency:
HHS
Principal Investigator:
Robert N. Dehaven
Abstract:
DESCRIPTION (provided by applicant): Pain is a serious, debilitating condition that is under treated because of the dose limiting side effects of currently used opiate therapeutics including respiratory depression, constipation, nausea, and physical dependence at… More

Novel Antagonists of the ORL-1 Receptor

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Diane L. Dehavenhudkins
Abstract:
N/a

Novel Antagonists of the ORL-1 Receptor

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$822,158.00
Agency:
HHS
Principal Investigator:
Diane L. Dehavenhudkins
Abstract:
N/a